DAIICHI SANKYO GROUP
DAIICHI SANKYO GROUP, a prominent player in the global pharmaceutical industry, is headquartered in Japan (JP) and operates extensively across Asia, Europe, and the Americas. Founded in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company, Limited, the group has since achieved significant milestones, including advancements in oncology and cardiovascular treatments. Specialising in innovative medicines, DAIICHI SANKYO is renowned for its unique drug development capabilities, particularly in targeted therapies and biologics. The company’s commitment to research and development has positioned it as a leader in the pharmaceutical market, with notable achievements such as the successful launch of several blockbuster drugs. With a strong focus on improving patient outcomes, DAIICHI SANKYO continues to make strides in the healthcare sector, solidifying its reputation as a trusted name in pharmaceuticals.
DitchCarbon Score
How does DAIICHI SANKYO GROUP's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
DAIICHI SANKYO GROUP's score of 39 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
DAIICHI SANKYO GROUP's reported carbon emissions
In 2023, DAIICHI SANKYO GROUP reported total carbon emissions of approximately 4,430,241,000 kg CO2e, with emissions distributed across various scopes: 85,245,000 kg CO2e (Scope 1), 23,994,000 kg CO2e (Scope 2), and a significant 4,430,241,000 kg CO2e (Scope 3). This marked an increase in Scope 3 emissions compared to previous years, indicating a growing impact from purchased goods and services. The company has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 63% by FY2030 from a FY2015 baseline. Additionally, DAIICHI SANKYO plans to transition to 100% renewable electricity sourcing by FY2030, up from 4% in FY2015. Furthermore, they aim for 70.6% of their suppliers, based on emissions, to establish science-based targets by FY2025. These targets align with the Science Based Targets initiative (SBTi) and are consistent with the reductions necessary to limit global warming to 1.5°C. DAIICHI SANKYO's commitment to sustainability reflects its proactive approach in addressing climate change within the pharmaceutical sector, headquartered in Japan.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 86,785,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 96,080,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 609,954,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
DAIICHI SANKYO GROUP is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
